RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Recursion Pharmaceuticals, Inc. ( NASDAQ: RXRX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT ...

Recursion Pharmaceuticals (RXRX 0.02%), a biotech company focused on artificial intelligence (AI), went public in April 2021. This was before ChatGPT, before AI became the hottest ...

Self-Referential Large Models: Recursive Self-Enhancement in Code Generation ...

Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia –– Extends Cash Runway through 2027 –NEW ...

Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was ...

Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the pharma says can help young drugmakers while training its own models.

The most profound failures in history are not those that bet big and lost, but those that failed to bet at all. Incremental advances will never cure Alzheimer’s disease or reverse climate change. To ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. The company was the target of an analyst price ...

Absci's AI-driven drug discovery platform, its potential, challenges, and strategic partnerships. Read here for an investment analysis of ABSI stock.